Deepu Daniel, DO
Nephrology · Lawrenceville, GANPI 1447679808
Payments from drug & device makers
Across 169 payments — averaging $21.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Akebia Therapeutics Inc$507
- Amgen$412
- Fresenius USA Marketing, Inc.$337
- Bayer$280
- AstraZeneca$244
- Otsuka America Pharmaceutical, Inc.$197
- plus $2K from 22 others
What the payments were for
- Food & beverage$3,37095%
- Education$1855%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Akebia Therapeutics Inc | 24 | $507 |
| Amgen(2 entities) | 19 | $412 |
| Fresenius USA Marketing, Inc. | 17 | $337 |
| Bayer | 12 | $280 |
| AstraZeneca(2 entities) | 14 | $244 |
| Otsuka America Pharmaceutical, Inc. | 8 | $197 |
| Aurinia Pharma U.S., Inc. | 7 | $174 |
| Vifor Pharma, Inc. | 7 | $160 |
| Boehringer Ingelheim | 6 | $130 |
| Daiichi Sankyo Inc. | 5 | $127 |
| Novo Nordisk | 5 | $110 |
| Otsuka Pharmaceutical Development & Commercialization, Inc. | 1 | $103 |
| Travere Therapeutics, Inc. | 13 | $102 |
| OPKO Pharmaceuticals, LLC | 5 | $96 |
| Lilly USA, LLC | 4 | $89 |
| Scpharmaceuticals Inc. | 3 | $88 |
| Novartis | 4 | $68 |
| Mallinckrodt Hospital Products Inc. | 2 | $66 |
| Calliditas Therapeutics US Inc. | 3 | $62 |
| GSK | 2 | $41 |
| Ardelyx, Inc. | 1 | $27 |
| Apellis Pharmaceuticals, Inc. | 1 | $25 |
| Sanofi | 1 | $23 |
| Shire North American Group Inc | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Boston Scientific | 1 | $17 |
| ANI Pharmaceuticals, Inc. | 1 | $16 |
| Kyowa Kirin, Inc. | 1 | $16 |
How this compares
$3,554 in reported general payments places this provider in the 65th percentile of 388 nephrology providers in Georgia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KrystexxaPegloticase | 14 | $510,713 |
| FarxigaDapagliflozin Propanediol | 284 | $259,768 |
| JardianceEmpagliflozin | 227 | $202,812 |
| KerendiaFinerenone | 148 | $150,233 |
| AuryxiaFerric Citrate | 41 | $137,374 |
| VelphoroSucroferric Oxyhydroxide | 34 | $117,251 |
| OzempicSemaglutide | 48 | $66,152 |
| RybelsusSemaglutide | 25 | $35,019 |
| LokelmaSodium Zirconium Cyclosilicate | 32 | $18,592 |
| VeltassaPatiromer Calcium Sorbitex | 11 | $14,037 |
| TrulicityDulaglutide | 12 | $11,447 |
| DapagliflozinDapagliflozin Propanediol | 16 | $11,010 |
| Sevelamer Carbonate | 14 | $2,860 |
| Chlorthalidone | 87 | $1,473 |
| Nifedipine ErNifedipine | 27 | $1,070 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AmgenKrystexxa | $412 | $510,71314 claims |
| AstraZenecaFarxiga, Lokelma | $244 | $278,360316 claims |
| Boehringer IngelheimJardiance | $130 | $202,812227 claims |
| BayerKerendia | $280 | $150,233148 claims |
| Akebia Therapeutics IncAuryxia | $507 | $137,37441 claims |
| Fresenius USA Marketing, Inc.Velphoro | $337 | $117,25134 claims |
| Novo NordiskOzempic, Rybelsus | $110 | $101,17173 claims |
| Lilly USA, LLCTrulicity | $89 | $11,44712 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 388 nephrology providers in Georgia.
Other nephrology in Lawrenceville
- James TumlinLawrenceville$19.8M
- Kirti ShahLawrenceville$266K
- Ayorinde SoipeLawrenceville$218K
- William PaxtonLawrenceville$85K
- Lorin SanchezLawrenceville$76K
- Sharad VirmaniLawrenceville$55K
- Aakash AminLawrenceville$22K
- Chinedu NwekeAcworth$3.9M
- Vinayak RamanathLagrange$3.1M
- Harold HubertAugusta$2.8M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.